Literature DB >> 2231000

Myocardial uptake of indium-111-labeled antimyosin in acute subendocardial infarction: clinical, histochemical, and autoradiographic correlation of myocardial necrosis.

R C Hendel1, B A McSherry, J A Leppo.   

Abstract

Indium-111-labeled antimyosin has been utilized in the diagnosis and localization of acute transmural myocardial infarction. The present report describes a patient who presented with a massive subendocardial infarction. Two days after the injection of antimyosin, the patient's clinical status markedly deteriorated and he expired. Postmortem examination demonstrated severe three-vessel coronary artery disease with extensive myocyte death in the endocardium. Autoradiography and histochemical staining of the prosected heart demonstrated high correlation for myocardial necrosis and corresponded to clinical evidence for diffuse subendocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2231000

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

Review 1.  Clinical role of indium-111 antimyosin imaging.

Authors:  S Bhattacharya; A Lahiri
Journal:  Eur J Nucl Med       Date:  1991

2.  Quantitative 111In antimyosin antibody imaging to predict the age of myocardial infarction.

Authors:  S Bhattacharya; R Senior; X J Liu; D Jain; A Lahiri
Journal:  Int J Card Imaging       Date:  1992

3.  Transcapillary exchange of indium 111-labeled anticardiac myosin Fab and thallium 201 in isolated reperfused rabbit hearts.

Authors:  D J Meerdink; J A Leppo
Journal:  J Nucl Cardiol       Date:  1994 May-Jun       Impact factor: 5.952

Review 4.  Rationale for the rational development of new cardiac imaging agents.

Authors:  D D Miller
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

5.  Indium-111 antimyosin monoclonal antibody Fab imaging in patients with cardiomyopathy.

Authors:  M Ishibashi; T Wada; S Morita; Y Koga; S Tanaka; N Umezaki; H Toshima; N Hayabuchi
Journal:  Ann Nucl Med       Date:  1995-02       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.